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in 37 non cardiovascular (urinary tract 7 pts, gastrointestinal 18 pts,mixed surg 12).
Primart EP :0 (97,5% CI 6,4%). Bleeding events : 2 major, according TIMI criteria
(gastrointesinal surg), 2 minor, trasfusion in 11 pts. Severe thrombocitopenia (platelet
count < 20.000): 1 pt.
Conclusion: Based on the results of our prospective study we propose that a “bridge
strategy” using short-acting i.v. antiplatelet agents confers protection against
perioperative CV events that goes beyond the prevention of stent thrombosis, without
increasing the risk of bleeding, in pts in DAPT, planned for urgent surgery < = 12
months after DES implantation.
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Background: It remains unknown whether high-risk cohorts undergoing percutaneous
coronary intervention (PCI) are at an increased risk of adverse events after clopidogrel
cessation. We assessed the rates of adverse events after stopping clopidogrel treatment
in patients who had undergone saphenous vein graft (SVG) PCI.
Methods: We identified patients undergoing SVG PCI between 2000-2009 in an
integrated pre-paid health care plan. Clopidogrel utilization was ascertained from
pharmacy records. The date of the prescription and quantity of tablets dispensed were
recorded for every clopidogrel prescription filled by the patient post-PCI. A
multivariate Cox regression model was constructed to obtain risk-adjusted
instantaneous incidence rates using kernel hazard functions. The following covariates
were included in the model: age, gender, comorbidities, clopidogrel duration and non-
compliance, and use of concomitant medications (beta blockers, statins, and others).
Results: Among 603 patients who underwent SVG PCI during the study period, 403
were event free at the time of clopidogrel cessation and comprised the study cohort.
Risk-adjusted instantaneous incidence rates for death or myocardial infarction after
stopping clopidogrel treatment are shown in the figure. The risk of an adverse event
appears to be greatest early after cessation of clopidogrel therapy, regardless of stent
type.
Conclusion: A clustering of events was observed in the near-term after clopidogrel
cessation in patients treated with either drug-eluting or bare metal stents. Additional
studies are needed to confirm these findings and determine the responsible
mechanisms.
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Background: Context High residual platelet reactivity (HRPR) on clopidogrel has
been associated with high risk of ischemic events after percutaneous coronary
intervention (PCI). To test the hypothesis that HRPR after clopidogrel loading would
be an independent prognostic marker of risk of long-term thrombotic events in patients
with acute coronary syndrome (ACS) receiving an invasive treatment and
antithrombotic treatment adjusted according to the results of platelet function tests.
Methods: Prospective, observational, referral center cohort study of 1789 consecutive
ACS patients undergoing PCI from April 2005 to April 2009, and for whom platelet
reactivity was prospectively assessed by light transmittance aggregometry. Patients
with HRPR by ADP test (≥ 70%) received an increased dose of clopidogrel (from 150
mg/daily to 300 mg/daily), or shifted to ticlopidine (500mg/daily to 1000 mg/daily),
under ADP test guidance (clinicaltrials.gov Identifier: NCT01231035). The primary
end point was the composite of cardiac death, myocardial infarction, any urgent
coronary revascularization, and stroke at 2-year follow-up. Secondary end points were
stent thrombosis, and each component of the primary end point.
Results: The primary end point rate was 14.6% in the HRPR group and 8.7% in the
low residual platelet reactivity group (p = 0.003). Stent thrombosis rate was higher in
the HRPR group as compared to the low residual platelet reactivity group (6.1% vs
2.9%, p = 0.001). By multivariable analysis, HRPR was an independent predictor of
the primary end point (HR1.49, 95% CI 1.08-2.05, p = 0.015) and of cardiac mortality
(HR 1.81, 95% CI 1.18-2.76, p = 0.006).
Conclusion: HRPR is a strong predictor of short- and long-term ischemic events,
including stent thrombosis. Antiplatelet therapy using increased maintenance dose of
clopidogrel or ticlopidine, has no impact on clinical outcome.
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Background: ST-elevation myocardial-infarction (STEMI) patients show an
attenuated platelet inhibition to clopidogrel 600 mg-loading dose. It could be
hypothesized that STEMI patients with cardiogenic shock may even respond worse to
standard clopidogrel loading. Thus, the aim of this study was to compare platelet
inhibition in STEMI patients with and without cardiogenic shock after clopidogrel
loading.
Methods: In this study, 237 consecutive STEMI patients (207 without cardiogenic
shock and 30 with cardiogenic shock) were evaluated regarding their platelet inhibition
using the Multiplate analyzer. Cardiogenic shock was defined as hemodynamic
instability with need for catecholamines or intubated patients with clopidogrel 600mg-
loading over nasogastric tube. We further assessed the number of primary clopidogrel
low-responders (defined as >468 AU*min) and their response to an additional
clopidogrel 600 mg-loading, and if necessary, to a further prasugrel 60 mg-loading.
Results: Platelet inhibition after clopidogrel 600 mg-loading was less effective for
STEMI patients with cardiogenic shock (median 643 AU*min, interquartile range 448-
1009) compared to those without cardiogenic shock (median 492 AU*min, interquartile
range 222-822) (P=0.04). Platelet inhibition after prasugrel 60 mg-loading was highly
effective in primary clopidogrel low responders.
Conclusion: Clopidogrel-induced platelet inhibition was significantly less effective
for STEMI patients with cardiogenic shock compared to those without cardiogenic
shock. Prasugrel was effective in primary clopidogrel low responders and may
represent a better choice for STEMI patients with cardiogenic shock leading to highly
activated platelets and impaired resorption and metabolization.
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Background: Bleeding complications after percutaneous coronary intervention (PCI)
have been associated with increased mortality. These data have been derived in the
context of using Bivalirudin (BIV) versus heparin + GPIIb/IIIa inhibitors after PCI
and especially STEMI. We studied the predictors of mortality after PCI in a population
treated exclusively with BIV and we investigated the role of anemia on clinical
outcomes.
Methods: We evaluated 11,991 patients who underwent PCI from July 2001 to May
2010 with bivalirudin as the primary antithrombotic agent. Bleeding complications
were prospectively collected and defined by the criteria used in The Harmonizing
Outcomes with Revascularization and Stents in Acute Myocardial Infarction
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(HORIZONS-AMI) study. Cox regression analysis was performed to adjust for
covariates which were significant univariate predictors of mortality.
Results: According to the WHO anemia definition, 4815 (40%) patient had baseline
anemia. The incidence of major bleeding was 3.3% in patients with anemia compared
to 0.7% in patients without anemia (p<0.001). By multivariate analysis, major bleeding
was a significant predictor of mortality (HR 1.4, 95% CI: 1.04-1.8; p=0.027) in the
total study population at 2.3 years of follow up (interquartile range 1.4 to 3.5 years).
Among patients with anemia, major bleeding remained a strong and independent
predictor of mortality (HR 1.5, 95% CI: 1.1-2.0; p=0.008). However, among patients
without anemia, major bleeding was no longer a significant predictor of mortality (HR
1.25, 95% CI: 0.52-3.03; p=0.62).
Multivariate predictors of mortality in anemic and non anemic subgroups.
Conclusion: In patients undergoing PCI with Bivalirudin therapy, major bleeding is
associated with early and long term mortality. This association is linked with and
related to baseline anemia. Further studies are needed to study this important
association.
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Background: Post-treatment platelet reactivity(PR) is associated with major adverse
cardiovascular events(MACE) following percutaneous coronary intervention(PCI) in
the clopidogrel era. Prasugrel is a new P2Y12-ADP receptor which induces a higher
platelet reactivity inhibition. We aimed to investigate the relationship between PR
following a prasugrel loading dose(LD) and thrombotic events.
Methods: A prospective multicentre study included 301 patients that had successful
PCI for an acute coronary syndrome(ACS) and received prasugrel therapy. Vasodilator-
Stimulated Phosphoprotein(VASP index) was measured after prasugrel LD. High
on-Treatment PR(HTPR) was defined as a VASP≥50%. MACE included
cardiovascular death, myocardial infarction and definite stent thrombosis at one month.
Results: The mean VASP following prasugrel LD was 34.3±23.1%. HTPR was
observed in 76 patients(25.2%). Patients experiencing a thrombotic event following
PCI had a significantly higher VASP index compared to those free of event(64.4 ±14.4
vs 33.4±22.7%; range 51–64 and 5–47.6 respectively; p=0.001). Kaplan-Meier analysis
comparing good responders and patients with HTPR demonstrated a significantly
higher rate of MACE in patients with HTPR(log rank p<0.001). Patients with minor
or major non-CABG related TIMI bleeding and those without had similar VASP index
(30±17.8 vs 34.3±23.%;p=0.7).
Conclusion: Despite the use of prasugrel a significant number of patients undergoing
PCI in the setting of acute coronary syndromes do not achieve an optimal PR inhibition.
Such patients have a higher risk of MACE following PCI.
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Practice. Results of the Prospective ATACS Registry
Uwe Zeymer, Anselm Gitt, Ralf Zahn
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Background: In the TRITON-TIMI 38 study prasugrel compared to clopidogrel
reduced death, reinfarction and reinfarction in patients with STEMI undergoing
primary PCI without increasing bleeding complications. Little is known about use and
results of prasugrel in real world clinical practice.
Methods: Methods: In the prospective ATACS registry patients with STEMI < 24
hours undergoing angiography and subsequent PCI if feasible were enrolled in 27
hospitals in Germany. Timing and dosing were recorded as well as procedural features
and inhospital outcomes. Data were centrally collected and analysed.
Results: Between Oct 2009 and December 2010 a total of 1000 patients with STEMI
who underwent angiography were included. 713 (71%) were treated with clopidogrel,
287 (29%) with prasugrel. In clopidogrel treated patients a 600 mg loading was given
in 94 % and 300 mg in 5 % of the patients. Prasugrel with a loading dose of 60 mg
was administered in 95%, other loading doses in 5 % of the patients. A PCI was
performed in 924 (92 %) patients, 657 with clopidogrel and 267 with prasugrel. A stent
was implantated in 95 % of the patients with PCI. Aspirin was given in 99% of patients
and a GP IIb/IIIa inhibitor in 45 % with prasugrel and 47 % with clopidogrel. The
unadjusted in-hospital event rates in patients with PCI are shown in the table.
Inhospital events
Conclusion: In real world clinical practice prasugrel in patients with primary PCI for
STEMI is safe and associated with an improved clinical outcome compared to
clopidogrel supporting the findings of the randomized clinical trial.
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